Furmonertinib is a Class 1 innovative drug developed by Allist that is intended to be used for the treatment of adult patients of locally advanced or metastatic non-small cell lung cancer (NSCLC) who experience progression during or following prior therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy with confirmed EGFR T790M positive mutations. Furmonertinib is a third-generation EGFR-TKI with independent intellectual property right, which was approved by the National Medical Products Administration (NMPA) in March 2021.

Furmonertinib was approved by the National Medical Products Administration (NMPA) of China for use in the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations on June.29, 2022.